{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:47:02Z","timestamp":1791848822520,"version":"4.3.4"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Almost 50% of patients with skin psoriasis have concomitant nail involvement. The comparative effectiveness of the available biologics for nail psoriasis (NP) is still an area of contention because of limited data on nails.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We conducted a systematic review and network meta-analysis (NMA) to compare the efficacy of biologics in achieving complete resolution of NP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified studies in PubMed, EMBASE and Scopus. The eligibility criteria included randomized controlled trial (RCTs) or cohort studies for psoriasis or psoriatic arthritis with at least two arms of active comparator of biologic reporting at least one efficacy outcome of interest: that is the Nail Psoriasis Severity Index (NAPSI), the modified NAPSI or the Physician's Global Assessment of Fingernail Psoriasis with a score of 0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fourteen studies comprising seven treatments met the inclusion criteria, and were included in the NMA. The NMA showed the odds of complete NP resolution were superior with ixekizumab [risk ratio (RR) 1.4, 95% confidence interval (CI) 0.73\u20133.10] compared with the treatment of reference (adalimumab). Brodalumab (RR 0.92, 95% CI 0.14\u20137.40), guselkumab (RR 0.81, 95% CI 0.40\u20131.80), infliximab (RR\u00a00.90, 95% CI 0.19\u20134.60) and ustekinumab (RR 0.33, 95% CI 0.08\u20131.60) demonstrated worse therapeutic effect compared with adalimumab. According to the surface under the cumulative ranking curve, ixekizumab 80\u2005mg every 4 weeks had the highest probability of being the best treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The interleukin-17A inhibitor ixekizumab has the highest rate of complete nail clearance and it can be considered the best-ranked therapy from the present evidence. This study is relevant to daily practice as it facilitates the decision when choosing between the wide variety of available biologics in patients for whom clearance of nail symptoms is the first concern.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llad136","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T09:43:57Z","timestamp":1681379037000},"page":"895-902","source":"Crossref","is-referenced-by-count":19,"title":["Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis"],"prefix":"10.1093","volume":"48","author":[{"given":"Husein","family":"Husein-ElAhmed","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Hospital de Baza , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Husein-ElAhmed","sequence":"additional","affiliation":[{"name":"Montefr\u00edo Health Center , Andalusian Health Service, Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"2023101015412723200_llad136-B1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000507298","article-title":"Small molecules and biologics in the treatment of nail psoriasis","volume":"6","author":"Rigopoulos","year":"2020","journal-title":"Skin Appendage Disord"},{"key":"2023101015412723200_llad136-B2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5114\/reum.2017.68912","article-title":"Nail involvement in psoriatic arthritis","volume":"55","author":"Sobolewski","year":"2017","journal-title":"Reumatologia"},{"key":"2023101015412723200_llad136-B3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med"},{"key":"2023101015412723200_llad136-B4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000182250","article-title":"The nail as a musculoskeletal appendage \u2013 implications for an improved understanding of the link between psoriasis and arthritis","volume":"218","author":"McGonagle","year":"2009","journal-title":"Dermatology"},{"key":"2023101015412723200_llad136-B5","doi-asserted-by":"crossref","first-page":"146","DOI":"10.36849\/JDD.4969","article-title":"Treatment of nail psoriasis","volume":"21","author":"Kassir","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"2023101015412723200_llad136-B6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaad.2021.01.024","article-title":"Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis","volume":"85","author":"Huang","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023101015412723200_llad136-B7","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1080\/09546634.2021.1892024","article-title":"Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis","volume":"33","author":"Reich","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2023101015412723200_llad136-B8","article-title":"Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12\/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: a network meta-analysis","volume":"100","author":"Szeb\u00e9nyi","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2023101015412723200_llad136-B9","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2023101015412723200_llad136-B10","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2023101015412723200_llad136-B11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023101015412723200_llad136-B12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study","volume":"79","author":"Leonardi","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023101015412723200_llad136-B13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023101015412723200_llad136-B14","first-page":"952","article-title":"Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study","volume":"40","author":"Nash","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2023101015412723200_llad136-B15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/1346-8138.12229","article-title":"Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study","volume":"40","author":"Ozmen","year":"2013","journal-title":"J Dermatol"},{"key":"2023101015412723200_llad136-B16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"2023101015412723200_llad136-B17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial","volume":"28","author":"Paul","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023101015412723200_llad136-B18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023101015412723200_llad136-B19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jdv.14738","article-title":"Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study","volume":"32","author":"Reich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023101015412723200_llad136-B20","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjd.17351","article-title":"Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023101015412723200_llad136-B21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study","volume":"184","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023101015412723200_llad136-B22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13555-021-00520-0","article-title":"Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results","volume":"11","author":"Umezawa","year":"2021","journal-title":"Dermatol Ther (Heidelb"},{"key":"2023101015412723200_llad136-B23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s13555-021-00654-1","article-title":"Nail involvement as a predictor of differential treatment effects of secukinumab versus ustekinumab in patients with moderate to severe psoriasis","volume":"12","author":"Conrad","year":"2022","journal-title":"Dermatol Ther (Heidelb"},{"key":"2023101015412723200_llad136-B24","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000582","article-title":"4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis","volume":"4","author":"van der Heijde","year":"2018","journal-title":"RMD Open"},{"key":"2023101015412723200_llad136-B25","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s10067-018-4227-7","article-title":"Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4\u2005years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial","volume":"37","author":"Walsh","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023101015412723200_llad136-B26","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjd.16050","article-title":"Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)","volume":"178","author":"Papp","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023101015412723200_llad136-B27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/bjd.21233","article-title":"Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis","volume":"187","author":"Reich","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023101015412723200_llad136-B28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","article-title":"Efficacy and safety of ixekizumab with or without methotrexate in biologic-na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study","volume":"7","author":"Smolen","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2023101015412723200_llad136-B29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","article-title":"Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials","volume":"154","author":"Foley","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2023101015412723200_llad136-B30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023101015412723200_llad136-B31","article-title":"Efficacy and safety of ixekizumab versus adalimumab in biologic-na\u00efve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H Trial","volume":"12","author":"Reich","year":"2022","journal-title":"Dermatol Pract Concept"},{"key":"2023101015412723200_llad136-B32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J Rheumatol"},{"key":"2023101015412723200_llad136-B33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023101015412723200_llad136-B34","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023101015412723200_llad136-B35","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","article-title":"Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"59","author":"Chandran","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2023101015412723200_llad136-B36","first-page":"958","article-title":"Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3","volume":"15","author":"Dennehy","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"2023101015412723200_llad136-B37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2020.1749546","article-title":"Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials","volume":"33","author":"Elewski","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2023101015412723200_llad136-B38","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s13555-022-00704-2","article-title":"Simultaneous nail and skin clearance in ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis","volume":"12","author":"Elewski","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023101015412723200_llad136-B39","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","article-title":"Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2023101015412723200_llad136-B40","first-page":"109","article-title":"Ixekizumab demonstrates consistent efficacy versus adalimumab in biologic disease-modifying anti-rheumatic drug-na\u00efve psoriatic arthritis patients regardless of psoriasis severity: 52-week post hoc results from SPIRIT-H2H","volume-title":"Rheumatol Ther","author":"Kristensen","year":"2022"},{"key":"2023101015412723200_llad136-B41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023101015412723200_llad136-B42","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"Br J Dermatol"},{"key":"2023101015412723200_llad136-B43","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023101015412723200_llad136-B44","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14712598.2013.736960","article-title":"TNF-\u03b1 antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis","volume":"13","author":"Saraceno","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"2023101015412723200_llad136-B45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/jdv.14033","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3","volume":"31","author":"van de Kerkhof","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023101015412723200_llad136-B46","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s13555-020-00383-x","article-title":"Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S)","volume":"10","author":"Wasel","year":"2020","journal-title":"Dermatol Ther (Heidelb"},{"key":"2023101015412723200_llad136-B47","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"1","author":"Sbidian","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023101015412723200_llad136-B48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/keh198","article-title":"Extended report: nail disease in psoriatic arthritis \u2013 clinically important, potentially treatable and often overlooked","volume":"43","author":"Williamson","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2023101015412723200_llad136-B49","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"2023101015412723200_llad136-B50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220868","article-title":"Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response","volume":"14","author":"Sawyer","year":"2019","journal-title":"PLoS One"},{"key":"2023101015412723200_llad136-B51","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjd.15831","article-title":"Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review","volume":"178","author":"Busard","year":"2018","journal-title":"Br J Dermatol"},{"key":"2023101015412723200_llad136-B52","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"PASI90 response: the new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023101015412723200_llad136-B53","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/jdv.15793","article-title":"Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial","volume":"33","author":"Elewski","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023101015412723200_llad136-B54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail psoriasis: a review of treatment options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"key":"2023101015412723200_llad136-B55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jaad.2007.07.042","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1\u2005year","volume":"58","author":"Rich","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2023101015412723200_llad136-B56","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023101015412723200_llad136-B57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(94)92273-X","article-title":"Is there logic in the placebo","volume":"344","author":"Gotzsche","year":"1994","journal-title":"Lancet"},{"key":"2023101015412723200_llad136-B58","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0895-4356(01)00496-6","article-title":"What are the main methodological problems in the estimation of placebo effects?","volume":"55","author":"Hrobjartsson","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"2023101015412723200_llad136-B59","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"2023101015412723200_llad136-B60","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5195","article-title":"The effects of excluding treatments from network meta-analyses: survey","volume":"347","author":"Mills","year":"2013","journal-title":"BMJ"},{"key":"2023101015412723200_llad136-B61","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/EDE.0000000000000482","article-title":"Sensitivity to excluding treatments in network meta-analysis","volume":"27","author":"Lin","year":"2016","journal-title":"Epidemiology"},{"key":"2023101015412723200_llad136-B62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/ACI.0b013e3283609831","article-title":"Post-hoc data analysis: benefits and limitations","volume":"13","author":"Curran-Everett","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad136\/50418461\/llad136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/8\/895\/51990315\/llad136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/8\/895\/51990315\/llad136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:42:02Z","timestamp":1696952522000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/8\/895\/7116750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4,13]]},"published-print":{"date-parts":[[2023,7,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad136","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,4,13]]}}}